Advanced Therapy for Hepatitis C

Herausgegeben von McCaughan, Geoffrey W.; McHutchinson, John; Pawlotsky, Jean-Michel

• Gebundenes Buch

Produktbeschreibung

According to the WHO, 170 million people, or 3% of the world's population, are infected with Hepatitis C and at risk of developing liver cirrhosis and/or liver cancer. 3-4 million people each year are newly diagnosed carriers of the virus.

Advanced Therapy for Hepatitis C Infection provides you with expert guidance from the world's leading hepatologists on the very latest treatment options for patients with the HCV virus. Focusing mainly on the efficacy and clinical use of antiviral therapies, key topics include:
Treatment of recurrent hepatitis C following liver transplantation
Antivirals in Cirrhosis and Portal Hypertension
HIV and Hepatitis C co-infection
Cytopenias: how they limit therapy and potential correction
The problem of insulin resistance and its effect on therapy
Antivirals in Acute Hepatitis C

In addition, it fully covers the foundations for understanding antiviral therapies in HCV, such as the complex pharmacology and mechanisms of antiviral drugs. Finally, a chapter on New Horizons: Interleukin 28 and direct-acting antiviral therapy for HCV, offers you a glimpse into the future possibilities for HCV therapy.

Edited by a team of outstanding international reputation, Advanced Therapy for Hepatitis C Infection is an essential tool for all hepatologists and gastroenterologists involved in the management of patients with Hepatitis C.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Wiley & Sons
• 1. Auflage
• Seitenzahl: 232
• Erscheinungstermin: 27. Dezember 2011
• Englisch
• Abmessung: 249mm x 191mm x 18mm
• Gewicht: 700g
• ISBN-13: 9781405187459
• ISBN-10: 140518745X
• Artikelnr.: 34159550

Autorenporträt

Professor Geoff McCaughan is Director of the AW Morrow Liver Centre and Physician in Charge at the Australian National Liver Transplant Unit. John McHutchison is a professor of medicine at Duke University Medical Center, and since 2002, Director of the DCRI's Gastroenterology and Hepatology Research division.

Inhaltsangabe

Contributors vii
Preface xi
Section I Foundations for Understanding Antiviral Therapies in HCV
1 HCV Replication 3
Michael R. Beard
2 Hepatitis C Virus Genotypes 12
Scott A. Read and Mark W. Douglas
3 Immune Responses to HCV: Implications for Therapy 17
David G. Bowen
4 Mechanisms of Action of Antiviral Drugs: The Interferons 25
Edmund Tse and Michael R. Beard
5 Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin
Analogs 36
Fred Poordad and Grace M. Chee
6 Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase
Inhibitors 43
Lotte Coelmont Leen Delang Mathy Froeyen Piet Herdewijn and Johan Neyts
7 Pharmacology and Mechanisms of Action of Antiviral Drugs: Protease
Inhibitors 53
Laurent Chatel-Chaix Martin Baril and Daniel Lamarre
8 Measuring Antiviral Responses 60
Jean-Michel Pawlotsky and Stephane Chevaliez
Section II Efficacy and Clinical Use of Antiviral Therapies
9 Genotype 1: Standard Treatment 67
Rebekah G. Gross and Ira M. Jacobson
10 Individually Tailored Treatment Strategies in Treatment-näive Chronic
Hepatitis C Genotype 1 Patients 74
Johannes Wiegand and Thomas Berg
11 Genotype 1 Relapsers and Non-responders 84
Salvatore Petta and Antonio Craxì
12 Standard Therapy for Genotypes 2/3 90
Kenneth Yan and Amany Zekry
13 Altered Dosage or Durations of Current Antiviral Therapy for HCV
Genotypes 2 and 3 97
Alessandra Mangia Leonardo Mottola and Angelo Andriulli
14 Genotypes 2 and 3 Relapse and Non-response 104
Stella Martinez Jose Maria Sanchez-Tapias and Xavier Forns
15 Hepatitis C Genotype 4 Therapy: Progress and Challenges 113
Sanaa M. Kamal
16 Antivirals in Acute Hepatitis C 127
Heiner Wedemeyer
17 Antivirals in Cirrhosis and Portal Hypertension 132
Diarmuid S. Manning and Nezam H. Afdhal
18 Treatment of Recurrent Hepatitis C Following Liver Transplantation 140
Ed Gane
19 Antiviral Treatment in Chronic Hepatitis C Virus Infection with
Extrahepatic Manifestations 150
Benjamin Terrier and Patrice Cacoub
20 Cytopenias: How they Limit Therapy and Potential Correction 160
Mitchell L. Shiffman
21 The Problem of Insulin Resistance and its Effect on Therapy 169
Venessa Pattullo and Jacob George
22 HIV and Hepatitis C Co-infection 177
Gail V. Matthews and Gregory J. Dore
23 HCV and Racial Differences 185
Andrew J. Muir
24 HCV and the Pediatric Population 190
Kathleen B. Schwarz
25 New Horizons: IL28 Direct-acting Antiviral Therapy for HCV 196
Alexander J. Thompson John G. McHutchison and Geoffrey W. McCaughan
Index 215